We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

51 hedge funds and large institutions have $121M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 1

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

82% more funds holding

Funds holding: 28 → 51 (+23)

72% more capital invested

Capital invested by funds: $70M → $121M (+$50.7M)

Holders
51
Holders Change
+23
Holders Change %
+82.14%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
10
Reduced
1
Closed
1
Calls
$86K
Puts
–
Net Calls
+$86K
Net Calls Change
+$86K

Top Buyers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
+$6.6M
2
SCM
Saba Capital Management
New York
+$5.73M
3
PC
Periscope Capital
Ontario, Canada
+$5M
4
DCM
DG Capital Management
New York
+$4.37M
5
RCM
Radcliffe Capital Management
Pennsylvania
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kingstown Capital Management
New York
-$2.92M
2
TCM
Tenor Capital Management
New York
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$1.45M +$583K +60,000 +67%
TI
27
Telemetry Investments
New York
$1.4M +$1.41M +144,683 New
TCM
28
Tenor Capital Management
New York
$1.39M -$1.33M -136,823 -49%
BCM
29
Basso Capital Management
Connecticut
$1.39M +$648K +66,661 +87%
Jane Street
30
Jane Street
New York
$1.28M +$256K +26,392 +25%
WA
31
Whitebox Advisors
Minnesota
$1.21M – – –
RIA
32
RP Investment Advisors
Ontario, Canada
$1.2M +$1.21M +124,469 New
CP
33
Centerbridge Partners
New York
$967K – – –
Marshall Wace
34
Marshall Wace
United Kingdom
$967K – – –
LP
35
LMR Partners
United Kingdom
$967K +$972K +100,000 New
CCA
36
Castle Creek Arbitrage
Colorado
$966K – – –
ACA
37
Arena Capital Advisors
California
$941K +$945K +97,272 New
AA
38
AQR Arbitrage
Connecticut
$859K +$863K +88,865 New
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$585K +$587K +60,459 New
MSU
40
Mizuho Securities USA
New York
$559K +$560K +57,650 New
LC
41
Littlejohn & Co
Connecticut
$484K +$486K +50,000 New
SSA
42
Schonfeld Strategic Advisors
New York
$484K +$486K +50,000 New
WRBC
43
W.R. Berkley Corp
Connecticut
$475K – – –
Millennium Management
44
Millennium Management
New York
$359K +$361K +37,151 New
EAM
45
Exos Asset Management
New York
$242K – – –
KIM
46
Karpus Investment Management
New York
$242K – – –
NAM
47
Nexpoint Asset Management
Texas
$230K +$231K +23,800 New
OMC
48
Old Mission Capital
Illinois
$103K +$103K +10,610 New
AA
49
Ancora Advisors
Ohio
$98K +$98.1K +10,100 New
MI
50
MMCAP International
Cayman Islands
$5.8K – – –
1
2
3

BIOT Hedge Fund Activity: Q2 2021 in Review

51 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q2 2021, worth a combined $121M — up 72% from $70M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new BIOT positions and 1 closed out — a net gain of 23 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was Linden Advisors, opening a new position worth an estimated $6.6M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $2.92M sold.

  • 51 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q2 2021, up from 28 in Q1 2021.
  • Funds reported $121M of Biotech Acquisition Company Class A Ordinary Shares stock for Q2 2021, up 72% quarter-over-quarter.
  • 24 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q2 2021 and 1 closed out, a net change of +23 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q2 2021 was Linden Advisors, an estimated $6.6M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q2 2021 was Kingstown Capital Management, an estimated $2.92M sold.

Based on aggregated 13F filings for Q2 2021.